Announcements Trials
Browse Landscape

Phase

Phase 1 2Phase 2 1

Status

Terminated 3Completed 3Unknown 2Recruiting 1

Sponsor Class

OTHER 2NIH 1

Study Type

Interventional 3

Sponsor

Cancer Type

Other hematologic neoplasm 127Myeloid 94Sarcoma 69Gastrointestinal 54Lymphoid 28Thoracic 16CNS 15Genitourinary 11Gynecologic 9Dermatologic 9Other solid neoplasm 7Breast 7Tumor-Agnostic 3Plasma cell 3Head & Neck 2Other 1

Conditions

Neoplasms 2Neoplasm Metastasis 1

Interventions

Paclitaxel 57Gemcitabine 51Carboplatin 51Surveys and Questionnaires 48Docetaxel 37Bevacizumab 37pembrolizumab 33Nivolumab 29Cisplatin 28Fluorouracil 24Capecitabine 23Irinotecan 22Erlotinib Hydrochloride 22Sorafenib 20Leucovorin 19Afatinib 19Radiotherapy 18Pemetrexed 18Oxaliplatin 17Trastuzumab 16Ipilimumab 15regorafenib 14Blood Specimen Collection 14130-nm albumin-bound paclitaxel 14olaparib 13Interviews as Topic 13Cetuximab 13Albumin-Bound Paclitaxel 13atezolizumab 12Sunitinib 12

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Completed × Imatinib Mesylate × Tumor-Agnostic × Clear all
NCT02142036 2019-03-13

MetAction

Oslo University Hospital

Phase 2 Completed
50 enrolled
Tumor-Agnostic

Neoplasm Metastasis

NCT00611689 2013-02-04

Imatinib and PTK787/ZK222584 in Refractory and/or Advanced Solid Tumors

SCRI Development Innovations, LLC

Phase 1 Completed
45 enrolled
Tumor-Agnostic

Neoplasms

NCT00026169 2013-01-10

Imatinib Mesylate in Treating Patients With Advanced Cancer and Kidney Failure

National Cancer Institute (NCI)

Phase 1 Completed
69 enrolled
Tumor-Agnostic

Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡